Your browser doesn't support javascript.
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
Richardson, Simone I; Manamela, Nelia P; Motsoeneng, Boitumelo M; Kaldine, Haajira; Ayres, Frances; Makhado, Zanele; Mennen, Mathilda; Skelem, Sango; Williams, Noleen; Sullivan, Nancy J; Misasi, John; Gray, Glenda G; Bekker, Linda-Gail; Ueckermann, Veronica; Rossouw, Theresa M; Boswell, Michael T; Ntusi, Ntobeko A B; Burgers, Wendy A; Moore, Penny L.
  • Richardson SI; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Manamela NP; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Motsoeneng BM; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Kaldine H; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Ayres F; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Makhado Z; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Mennen M; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Skelem S; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Williams N; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Sullivan NJ; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Misasi J; National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg 2131, South Africa.
  • Gray GG; SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2001, South Africa.
  • Bekker LG; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town 7701, South Africa.
  • Ueckermann V; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town 7701, South Africa.
  • Rossouw TM; Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town 7701, South Africa.
  • Boswell MT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Ntusi NAB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Burgers WA; The South African Medical Research Council, Tygerberg 7505, South Africa.
  • Moore PL; The Desmond Tutu HIV Centre, University of Cape Town, Cape Town 7705, South Africa.
Cell Rep Med ; 3(2): 100510, 2022 02 15.
Article in English | MEDLINE | ID: covidwho-1636907
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs) exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. However, while non-neutralizing cytotoxic functions of antibodies are associated with improved disease outcome and vaccine protection, Fc effector function escape from VOCs is poorly defined. Furthermore, whether VOCs trigger Fc functions with altered specificity, as has been reported for neutralization, is unknown. Here, we demonstrate that the Beta VOC partially evades Fc effector activity in individuals infected with the original (D614G) variant. However, not all functions are equivalently affected, suggesting differential targeting by antibodies mediating distinct Fc functions. Furthermore, Beta and Delta infection trigger responses with significantly improved Fc cross-reactivity against global VOCs compared with D614G-infected or Ad26.COV2.S-vaccinated individuals. This suggests that, as for neutralization, the infecting spike sequence affects Fc effector function. These data have important implications for vaccine strategies that incorporate VOCs, suggesting these may induce broader Fc effector responses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin Fc Fragments / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.XCRM.2022.100510

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin Fc Fragments / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.XCRM.2022.100510